Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial of Libtayo (cemiplimab) plus ...

The U.S. Food and Drug Administration (FDA) on Thursday granted Breakthrough Therapy designation to Eli Lilly and Co.’s (NYSE:LLY) olomorasib, in combination with Merck & Co. Inc.’s (NYSE:MRK) anti-PD ...

Akeso, Inc., a leading biopharmaceutical company announced that the National Medical Products Administration (NMPA) has accepted the supplementary New Drug Application (sNDA) for ivonescimab ...

Roomba Max 705 Combo Provides heated mopping, 175x more suction power and first-of-its-kind cover protecting carpets from wet messes BEDFORD, Mass., July 22, 2025 /PRNewswire/ -- iRobot Corp. (NASDAQ: ...

As the newest and most advanced 2-in-1 vacuum and mop within iRobot's recently introduced suite of new Roomba robots, the Roomba Max 705 Combo conquers everyday messes - every day. At the heart of the ...

Football is the ultimate team game. A 53-man roster allows room for the most specifically gifted athletes to play a role, no matter how obscure. The Seattle Seahawks may have found one player who is ...

The consumer’s thirst for AI-based applications is powering the ever-evolving electronics industry. Applications delivering higher levels of information in human language-like form, smarter at-home ...

Peluntamig targets DLL3 and CD47, potentially enhancing immune recognition and attack on cancer cells. The SKYBRIDGE study is a phase 1/2 trial assessing peluntamig's safety and efficacy in ...

At 3 years, Opdivo plus Yervoy led to an overall survival rate of 38% in patients with unresectable or metastatic hepatocellular carcinoma, compared to 24% with lenvatinib or sorafenib monotherapy.

TUESDAY, April 15, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adults with unresectable or ...